RCT | Expectant management or early ibuprofen for patent ductus arteriosus.
9 Dec, 2022 | 13:38h | UTCExpectant Management or Early Ibuprofen for Patent Ductus Arteriosus – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this trial involving preterm infants with patent ductus arteriosus, expectant management was noninferior to ibuprofen therapy for the primary outcome of necrotizing enterocolitis, bronchopulmonary dysplasia, or death at 36 weeks. https://t.co/vzrpruce9F pic.twitter.com/fW09Sz8O8o
— NEJM (@NEJM) December 6, 2022